Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2

Conditions

Pancreatic Neoplasms 4Venous Thrombosis 3Pulmonary Embolism 3Venous Thromboembolism 2Thromboembolism 2Colorectal Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Hemorrhage 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Duodenal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Tinzaparin 3Gemcitabine 3Heparin, Low-Molecular-Weight 2Enoxaparin 2Dalteparin 2130-nm albumin-bound paclitaxel 2palbociclib 1isoquercitrin 1Watchful Waiting 1Rivaroxaban 1PEGPH20 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thromboembolism × Dalteparin × Gastrointestinal × Clear all
NCT00031837 2015-10-14

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

University of Rochester

Phase 3 Terminated
400 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

NCT00462852 2013-08-12

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡